Abstract
Recombinant factor VIIa (rFVIIa, NovoSeven) is FDA-approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A growing literature suggests that there may be expanded indications for the use of NovoSeven in patients with significant bleeding who do not have a known factor deficiency. Severe bleeding refractory to standard hematologic or hemostatic support is common in patients undergoing bone marrow transplantation (BMT). We review our experience with rFVIIa in three patients (8 years 8 months to 19 years, median 13 years) treated for pulmonary hemorrhage (n = 1), hemorrhagic cystitis (n = 3), and gastrointestinal bleeding (n = 2). Boluses of 90–270 μg/kg rVIIa with subsequent doses of 90 μg/kg every 4–24 h for 3–14 days were given, concurrent with maintaining platelet counts >50 000/mm3. Transient clinical responses in gross hematuria (two patients) and in pulmonary hemorrhage were noted within several days of starting rFVIIa, but bleeding in a new site in two patients and renewed bleeding of the initial site in the third resulted in discontinuation of the drug. No toxicity or adverse events were observed while the patients were on rFVIIa treatment. Because of the substantial cost of this product, the lack of adequate monitoring methodology, and the variability of current dose and dosing intervals, large randomized studies are needed before definitive off-label use in the setting of BMT can be recommended. Bone Marrow Transplantation (2001) 28, 405–407.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mariani G, Testa MG, Paolantonio T et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies Vox Sanguinis 1999 77: 131–136
Monroe DM, Hoffman M, Oliver JA, Roberts HR . Platelet activity of high-dose factor VIIa is independent of tissue factor Br J Haematol 1997 99: 542–547
Hedner U . Recombinant activated factor VII as a universal haemostatic agent Blood Coag Fibrin 1998 9: (Suppl. 1) S147–S152
White B, Martin M, Kelleher S et al. Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency Br J Haematol 1999 106: 254–255
Novo Nordisk Investigator's Brochure. Recombinant Coagulation Factor VIIa 1999 pp 42–47
Poon M-C, Katsarou O, Huth-Kuehne A et al. Recombinant Factor VIIa in congenital platelet bleeding disorders Proc Am Soc Hematol 2000 96: 256a
Chuansumrit A, Chantarojanasiri T, Isarangkura P et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation Blood Coag Fibrinol 2000 11: (Suppl. 1) S101–S105
Al Douri M, Shafi T, Al Khudairi D et al. Effect of theadministration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery Blood Coag Fibrinol 2000 11: (Suppl. 1) S121–S127
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blatt, J., Gold, S., Wiley, J. et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 28, 405–407 (2001). https://doi.org/10.1038/sj.bmt.1703157
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703157
Keywords
This article is cited by
-
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII
Medical Oncology (2010)
-
The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review
Bone Marrow Transplantation (2007)
-
Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding
Thrombosis Journal (2006)
-
Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning
Bone Marrow Transplantation (2006)
-
Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy
Bone Marrow Transplantation (2006)